{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:59:02Z","timestamp":1792619942516,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,10]]},"abstract":"<jats:p>\n                    Long-acting muscarinic antagonists (LAMAs) have been suggested as an additional treatment option for asthmatics inadequately controlled by inhaled corticosteroids and long-acting beta-agonists, though the specific patient characteristics that predict optimal LAMA responsiveness remain unclear. This study aims to identify predictors of response to tiotropium, one of LAMAs, in adult asthma patients. A retrospective analysis of 111 patients treated with tiotropium at a tertiary hospital (2009\u20132018) and a prospective study involving 18 patients were conducted. Response was defined as forced expiratory volume in 1 second (FEV1) improvement (\u226510% predicted or\u2005\u2265\u2005100\u2009mL) or absence of exacerbations. In the retrospective study, while overall FEV1 changes were minimal (\u221210\u2009mL, \u22120.33%), FEV1 responders (n\u2005=\u200521) showed significant increases (340\u2009mL, 10.3%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). FEV1 responders had lower baseline FEV1 compared to nonresponders (44.6\u2005\u00b1\u200513.0 vs 53.5\u2005\u00b1\u200515.5%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.031), and those with exacerbations had significantly lower baseline FEV1 (51.1\u2005\u00b1\u200518.2 vs 63.2\u2005\u00b1\u200525.7%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.008). In multivariate analysis, baseline FEV1\u2005&lt;\u200550% predicted remained an independent predictor of a positive FEV1 response (OR 3.5, 95% CI 1.1\u201311.6,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.037). The prospective study confirmed similar trends; FEV1 responders had lower baseline FEV1 (55.0\u2005\u00b1\u200517.5% vs 72.0\u2005\u00b1\u200516.7%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.04) and showed greater FEV1 improvements. Other factors, including eosinophil counts, immunoglobulin E levels, asthma-chronic obstructive pulmonary disease overlap, and smoking status, were not significant predictors of response. Tiotropium improved lung function, particularly in patients with lower baseline FEV1. Identifying such predictors can optimize patient selection for LAMA therapy. Further large-scale studies are needed to refine these findings.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000044912","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:03:05Z","timestamp":1760331785000},"page":"e44912","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Lower baseline FEV1 is associated with greater FEV1 improvement after tiotropium add-on in uncontrolled asthma"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8846-0364","authenticated-orcid":false,"given":"Ji-Su","family":"Shim","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Min","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1775-3733","authenticated-orcid":false,"given":"Min-Hye","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Joo","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20260113","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/COPD.S285867","article-title":"The impact of muscarinic receptor antagonists on airway inflammation: a systematic review.","volume":"16","author":"Calzetta","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R3-20260113","doi-asserted-by":"crossref","first-page":"210196","DOI":"10.1183\/16000617.0196-2021","article-title":"The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review.","volume":"31","author":"Calzetta","year":"2022","journal-title":"Eur Respir Rev"},{"key":"R4-20260113","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMoa1008770","article-title":"Tiotropium bromide step-up therapy for adults with uncontrolled asthma.","volume":"363","author":"Peters","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20260113","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.rmed.2016.06.013","article-title":"Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status.","volume":"117","author":"Kerstjens","year":"2016","journal-title":"Respir Med"},{"key":"R6-20260113","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","article-title":"Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.","volume":"394","author":"Virchow","year":"2019","journal-title":"Lancet"},{"key":"R7-20260113","doi-asserted-by":"crossref","first-page":"106021","DOI":"10.1016\/j.rmed.2020.106021","article-title":"Fixed-dose combination of indacaterol\/glycopyrronium\/mometasone furoate once-daily versus salmeterol\/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, Phase IIIb, non-inferiority study (ARGON).","volume":"170","author":"Gessner","year":"2020","journal-title":"Respir Med"},{"key":"R9-20260113","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R10-20260113","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers.","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur Respir J"},{"key":"R11-20260113","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","article-title":"Minimal clinically important differences in pharmacological trials.","volume":"189","author":"Jones","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"R12-20260113","first-page":"e13433","article-title":"Traditional medicines for asthma in children and adults: a systematic review of placebo-controlled studies [published online ahead of print].","author":"Clyne","year":"2019","journal-title":"Int J Clin Pract"},{"key":"R13-20260113","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.anai.2021.12.020","article-title":"Understanding the role of long-acting muscarinic antagonists in asthma treatment.","volume":"128","author":"Muiser","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R15-20260113","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1183\/13993003.00853-2015","article-title":"A summary of the new GINA strategy: a roadmap to asthma control.","volume":"46","author":"Reddel","year":"2015","journal-title":"Eur Respir J"},{"key":"R16-20260113","doi-asserted-by":"crossref","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline.","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"R17-20260113","first-page":"CD011721","article-title":"Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA\/ICS) versus LABA\/ICS for adults with asthma.","volume":"2016","author":"Kew","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R18-20260113","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2018.2757","article-title":"Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis.","volume":"319","author":"Sobieraj","year":"2018","journal-title":"JAMA"},{"key":"R19-20260113","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2147\/COPD.S308911","article-title":"A real world study to assess the effectiveness of switching to once daily closed triple therapy from mono\/dual combination or open triple therapy in patients with chronic obstructive pulmonary disease.","volume":"16","author":"Huang","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R20-20260113","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1001\/jama.2021.7872","article-title":"Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis.","volume":"325","author":"Kim","year":"2021","journal-title":"JAMA"},{"key":"R21-20260113","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.21037\/jtd.2019.09.22","article-title":"Clinical predictors of asthmatics in identifying subgroup requiring long-term tiotropium add-on therapy: a real-world study.","volume":"11","author":"Cheng","year":"2019","journal-title":"J Thorac Dis"},{"key":"R22-20260113","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaci.2013.08.003","article-title":"Predictors of response to tiotropium versus salmeterol in asthmatic adults.","volume":"132","author":"Peters","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R23-20260113","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1398-9995.2008.01876.x","article-title":"Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response.","volume":"64","author":"Park","year":"2009","journal-title":"Allergy"},{"key":"R24-20260113","doi-asserted-by":"crossref","first-page":"100720","DOI":"10.1016\/j.waojou.2022.100720","article-title":"Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: from multicenter real-world cohort data in Korea.","volume":"15","author":"Shim","year":"2022","journal-title":"World Allergy Organ J"},{"key":"R25-20260113","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.rmed.2016.01.012","article-title":"Bronchodilator response as a marker of poor asthma control.","volume":"112","author":"Heffler","year":"2016","journal-title":"Respir Med"},{"key":"R26-20260113","doi-asserted-by":"crossref","first-page":"446","DOI":"10.18176\/jiaci.0850","article-title":"Bronchodilator reversibility in the GAN severe asthma cohort.","volume":"33","author":"Milger","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R27-20260113","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.arbres.2023.05.015","article-title":"The new ERS\/ATS 2022 bronchodilator response recommendation: comparison with the previous version in an asthma cohort.","volume":"59","author":"Betancor","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"R28-20260113","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3390\/ph16111609","article-title":"Comprehensive observational study in a large cohort of asthma patients after adding LAMA to ICS\/LABA.","volume":"16","author":"Plaza","year":"2023","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:00:53Z","timestamp":1768334453000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":25,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044912","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"2025-05-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}